HOME >> MEDICINE >> NEWS
Leukemia drug breakthrough study in New England Journal of Medicine

Tampa, FL (Feb. 9, 2005) - Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in r
'"/>

Contact: Andrea Brunais
MediaRelations@moffitt.usf.edu
813-632-1478
University of South Florida Health
9-Feb-2005


Page: 1 2

Related medicine news :

1. Leukemia patients survive with stem cell transplant
2. Breakthrough New Therapy Uses Antibody-Targeted Chemotherapy To Fight Leukemia
3. Maxim Phase II Clinical Trial Highlights Substantial Increase In Leukemia-FreeSurvival For Acute Myelogenous Leukemia Patients
4. Promising New Drug Uses Antibody Targeted Chemotherapy To Fight Leukemia
5. University of Kentucky Markey Cancer Center Researchers Awarded Grant To Fight Leukemia Recurrence
6. OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia
7. Fertilization Protein Structure To AID in Leukemia Treatment
8. International gathering of experts to share retinoblastoma breakthroughs
9. Consumers to benefit from organic potato breakthrough
10. Biotech breakthrough in islet cell replacement for type 1 diabetes
11. 4 out of 5 eligible patients missing opportunity to benefit from latest HIV breakthrough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... ... 2017 , ... Happy Living’s mission - to improve the health and wellbeing ... entertaining and delicious worlds of theatre and wines. , After watching Scott Barry ... turn his play into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was ...
(Date:9/22/2017)... ... September 22, 2017 , ... "Success Files," a short- and ... Alzheimer’s is a disease estimated to affect the lives of more than 5 ... Alzheimer’s Association, a leading voice in the fight for cure and research into ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg freezing and ... frozen embryos have a slight statistical advantage for live births, frozen eggs offer ... opportunity for women undergoing medical treatment or who are concerned about the decline ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, M.D., ... Professional Member in recognition of his contributions to the ... as a Nephrologist at the practice of Kidney and ... kidney care and hypertension solutions. He has worked in ... of career experience, as well as expertise in kidneys, ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... 18 months after its February 2016 launch, market access ... of three new senior people to its rapidly expanding ... and James Wright bring decades of specialist ... Tammy Wynne joins as Director, Value Communication, ... over ten years, experience in global market access consultancy ...
Breaking Medicine Technology:
Cached News: